Ligand Pharmaceuticals Incorpor (LGND) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $207.78, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Hovione; Concentration risk — Product: Captisol material sales.
Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and licenses technologies to generate diversified royalty streams from high-value medicines. Revenue comes from royalties on partner-commercialized products (led by Kyprolis, Qarziba, Filspari),... Read more
Hold if already holding. Not a fresh buy at $207.78, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Hovione; Concentration risk — Product: Captisol material sales. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.38, quality 7.7/10, growth 8.0/10). | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 5.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Ligand Pharmaceuticals Incorpor
Material events (past 30 days)
- Apr 30, 2026 MEDIUM Item 1.02: Ligand terminated the TR-Beta Program under its Master License Agreement with Viking Therapeutics effective May 4, 2026, citing Viking's material breach of its obligation to use Commercially Reasonable Efforts to develop and commercialize the program.
Latest news
- RBC Capital raises Ligand Pharma stock price target on XOMA deal By Investing.com - Investing.com India — Investing.com India positive
- Ligand Pharmaceuticals (LGND) Is Up 13.3% After Securing 9% Royalty on Newly Approved FILSPARI - simplywall.st — simplywall.st positive
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI in FSGS - marketscreener.com — marketscreener.com positive
- LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $243 - GuruFocus — GuruFocus positive
- LGND Maintained at Buy by H.C. Wainwright, April 2026 - Meyka — Meyka positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierHovione10-K Item 1A: 'We obtain Captisol from Hovione, our third-party manufacturer, primarily at their facilities in Ireland and Portugal.'
- HIGHProductCaptisol material sales10-K Item 1A: 'Revenues from sales of Captisol material to our collaboration partners, including Amgen, represent approximately half of our royalty revenues.'
Material Events(8-K, last 90d)
- 2026-04-30Item 1.02MEDIUMLigand terminated the TR-Beta Program under its Master License Agreement with Viking Therapeutics effective May 4, 2026, citing Viking's material breach of its obligation to use Commercially Reasonable Efforts to develop and commercialize the program.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $207.78, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Hovione; Concentration risk — Product: Captisol material sales. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.38, quality 7.7/10, growth 8.0/10). | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Target $236.47 (+13.8%), stop $194.01 (−7.1%), A.R:R 1.5:1. Score 5.9/10, moderate confidence.
Take-profit target: $236.47 (+13.8% upside). Target $236.47 (+13.8%), stop $194.01 (−7.1%), A.R:R 1.5:1. Stop-loss: $194.01.
Concentration risk — Supplier: Hovione; Concentration risk — Product: Captisol material sales; Consecutive earnings misses (2).
Ligand Pharmaceuticals Incorpor trades at a P/E of 27.1 (forward 18.3). TrendMatrix value score: 5.2/10. Verdict: Hold.
14 analysts cover LGND with a consensus score of 4.3/5. Average price target: $272.
What does Ligand Pharmaceuticals Incorpor do?Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and licenses technologies to generate...
Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and licenses technologies to generate diversified royalty streams from high-value medicines. Revenue comes from royalties on partner-commercialized products (led by Kyprolis, Qarziba, Filspari), Captisol material sales, and contract revenue; total royalty receipts were $176.9M in 2025. The Captisol platform underpins 17 FDA-approved products and is sole-sourced from Hovione.